Overview

GLP3 (R) is a catalog shorthand that commonly refers to retatrutide (also known as LY3437943), an investigational peptide studied as a triple receptor agonist targeting:
GLP-1, GIP, and glucagon receptors.

Retatrutide is not FDA-approved and remains under clinical investigation. Trusted Peptides supplies this material strictly for research use only (RUO).

Key identifiers

• Primary name: Retatrutide
• Synonym: LY3437943
• CAS (commonly listed): 2381089-83-2
• Registry link: PubChem: Retatrutide

Research applications

In controlled laboratory settings, researchers use retatrutide (and related multi-agonists) to study:

• Incretin and glucagon receptor pharmacology (receptor activation, potency, pathway bias, second-messenger readouts)
• Systems metabolism models (e.g., energy balance endpoints in preclinical studies, model-dependent)
• Comparative profiling vs GLP-1-only and dual incretin agonists (assay-dependent)

Clinical research context (background only)

Clinical studies have evaluated retatrutide in obesity, reporting substantial weight reduction in a phase 2 trial and continued evaluation in phase 3 programs.
This information is provided strictly as scientific background and does not imply any approved or intended human use of RUO material.

• NEJM (2023): Phase 2 trial
• Lilly: “Retatrutide is not FDA-approved”
• ClinicalTrials.gov: Example phase 3 record

Form, documentation & storage

• Form: typically supplied as lyophilized powder (confirm exact form on your COA)
• Documentation: lot-specific COA should be used for identity/purity confirmation and traceability
• General storage: keep sealed, dry, protected from light; follow your lab’s SOPs and COA guidance

RUO disclaimer

For Research Use Only. Not for human or veterinary use. Not for diagnostic, therapeutic, or consumable use.